C63.02
BillableMalignant neoplasm of left epididymis
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is C63.02 an HCC code?
Yes. C63.02 maps to Melanoma and Other Skin Cancers under the CMS-HCC V28 risk adjustment model (and Breast, Prostate, and Other Cancers and Tumors under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for C63.02
For C63.02 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C63.02 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
C63.02 is the ICD-10-CM diagnosis code for malignant neoplasm of left epididymis. Cancer that develops in the left epididymis, the tube structure on the left side that stores and transports sperm. C63.02 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of male genital organs (c60-c63).
Under the CMS-HCC V28 risk adjustment model, C63.02 maps to Melanoma and Other Skin Cancers (HCC 23) with a community, non-dual, aged base RAF weight of 0.251. Under the older CMS-HCC V24 model, C63.02 maps to Breast, Prostate, and Other Cancers and Tumors (HCC 12) with a community, non-dual, aged base RAF weight of 0.150. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
The fifth character '2' specifies left side; ensure laterality is clearly documented in the medical record. Because C63.02 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C63.02 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •The fifth character '2' specifies left side; ensure laterality is clearly documented in the medical record
- •Epididymal cancer is rare; verify the diagnosis and site are correctly documented before coding
Clinical Significance
Left epididymal cancer is an extremely rare malignancy that requires both pathologic confirmation and specific laterality documentation. Like its right-sided counterpart, most left epididymal masses prove to be benign. The laterality-specific code provides maximum coding precision for this unusual diagnosis.
Documentation Requirements
- ✓Pathology confirming left epididymal malignancy
- ✓Histologic type and grade
- ✓Staging information
- ✓Primary vs. metastatic determination
- ✓Treatment plan